KR20190067918A - 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과 - Google Patents

채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과 Download PDF

Info

Publication number
KR20190067918A
KR20190067918A KR1020197015617A KR20197015617A KR20190067918A KR 20190067918 A KR20190067918 A KR 20190067918A KR 1020197015617 A KR1020197015617 A KR 1020197015617A KR 20197015617 A KR20197015617 A KR 20197015617A KR 20190067918 A KR20190067918 A KR 20190067918A
Authority
KR
South Korea
Prior art keywords
lipid
limited
active agent
alteration
cardiomyopathy
Prior art date
Application number
KR1020197015617A
Other languages
English (en)
Korean (ko)
Inventor
로렌스 헬슨
Original Assignee
사인패스 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/347,381 external-priority patent/US10117881B2/en
Application filed by 사인패스 파마 인코포레이티드 filed Critical 사인패스 파마 인코포레이티드
Publication of KR20190067918A publication Critical patent/KR20190067918A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197015617A 2016-11-09 2017-11-09 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과 KR20190067918A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/347,381 2016-11-09
US15/347,381 US10117881B2 (en) 2011-06-03 2016-11-09 Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
PCT/US2017/060936 WO2018089687A1 (fr) 2016-11-09 2017-11-09 Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des médicaments provoquant des canalopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025957A Division KR20200108371A (ko) 2016-11-09 2017-11-09 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과

Publications (1)

Publication Number Publication Date
KR20190067918A true KR20190067918A (ko) 2019-06-17

Family

ID=62109333

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197015617A KR20190067918A (ko) 2016-11-09 2017-11-09 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과
KR1020207025957A KR20200108371A (ko) 2016-11-09 2017-11-09 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과
KR1020237023240A KR20230110823A (ko) 2016-11-09 2017-11-09 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg,lysopg 및 lysopc의 보호 효과

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207025957A KR20200108371A (ko) 2016-11-09 2017-11-09 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과
KR1020237023240A KR20230110823A (ko) 2016-11-09 2017-11-09 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg,lysopg 및 lysopc의 보호 효과

Country Status (8)

Country Link
EP (1) EP3538106A4 (fr)
JP (1) JP2019533692A (fr)
KR (3) KR20190067918A (fr)
CN (1) CN110167562A (fr)
AU (1) AU2017357916B2 (fr)
CA (1) CA3042459C (fr)
MX (1) MX2019005141A (fr)
WO (1) WO2018089687A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
HRP20220536T1 (hr) * 2017-05-16 2022-06-10 Bow River LLC Liječenje pacijenta lijekom supstratom cyp3a4 koji je kontraindiciran za istodobnu primjenu s jakim inhibitorom cyp3a4
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
JP2024039728A (ja) * 2022-09-12 2024-03-25 賢一郎 蓮見 抗腫瘍免疫応答増強剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812312A (en) * 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
JPH10279487A (ja) * 1997-04-01 1998-10-20 Nippon Shokuhin Kako Co Ltd 脂質代謝改善剤
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
WO2012054718A2 (fr) * 2010-10-22 2012-04-26 The General Hospital Corporation Traitement du syndrome du qt long
WO2012167212A2 (fr) * 2011-06-03 2012-12-06 Signpath Pharma Inc. Atténuation liposomale du syndrome du qt long induit par un médicament et du courant de potassium à redressement retardé
US10117881B2 (en) * 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
EP3082768B1 (fr) * 2013-12-18 2023-02-22 Signpath Pharma Inc. Atténuation liposomale de l'inhibition induite par médicament du canal ikr cardiaque
EP3207931A3 (fr) * 2014-06-03 2017-12-20 Signpath Pharma Inc. Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre les médicaments provoquant des canalopathies

Also Published As

Publication number Publication date
JP2019533692A (ja) 2019-11-21
EP3538106A4 (fr) 2021-03-24
KR20230110823A (ko) 2023-07-25
AU2017357916B2 (en) 2020-11-26
WO2018089687A1 (fr) 2018-05-17
CN110167562A (zh) 2019-08-23
EP3538106A1 (fr) 2019-09-18
CA3042459A1 (fr) 2018-05-17
AU2017357916A1 (en) 2019-05-30
KR20200108371A (ko) 2020-09-17
MX2019005141A (es) 2019-09-26
CA3042459C (fr) 2022-08-16

Similar Documents

Publication Publication Date Title
US10117881B2 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
AU2017357916B2 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10357458B2 (en) Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
EP3151837B1 (fr) Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies
EP3082768B1 (fr) Atténuation liposomale de l'inhibition induite par médicament du canal ikr cardiaque
US10449193B2 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US11643424B2 (en) Cardiopathy-reducing phosphodiester lipids
US20230042703A1 (en) Cardioprotective Lipid and Method of Use
AU2017345473A1 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
EP3326616B1 (fr) Atténuation liposomale du syndrome du qt long induit par un médicament et du courant de potassium à redressement retardé
EP3697386B1 (fr) Compositions liquides pour l'usage péroral comprennant dérivés de phosphatidylglycerol et excipients thixotropiques pour le traitement de canalopaties cardiaques causeés par agents pharmacologiques
JP2024095746A (ja) 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X601 Decision of rejection after re-examination